30May

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, doubleblinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).


Abstract No : 1014

Abstract Type : Poster Discussion Session

Indication : Triple Negative Breast Cancer

Intervention : entinostat + atezolizumab

Company : Syndax Pharmaceutical Inc.

Technology : Monoclonal antibody


Results:

81 pts. were enrolled, median age 56 years (range 29-87), 69% received 1 prior line of therapy and 31% . 1 line. No significant difference in PFS per RECIST 1.1 was observed between ATEZO+ENT and ATEZO+P (median PFS 1.68 and 1.51 months, respectively [p = 0.64; HR 0.89, 95% CI: 0.53-1.48]), nor in any of the secondary efficacy endpoints (median PFS per irRECIST 1.68 vs 1.54 months; ORR 10.0% vs 2.4%; CBR 37.5% vs 31.7%; median OS 9.8 vs 12.4 months, respectively). Frequency of treatment-emergent adverse events (TEAEs), SAEs, discontinuations due to TEAE and TEAE with outcome death were higher in the ENT+ATEZO arm


Conclusion:

In pts. with previously treated aTNBC, median PFS was not prolonged when ENT was added to ATEZO compared to ATEZO and placebo, and the combination resulted in greater toxicity.


Commentary:

Entinostat + Atezolizumab did not improve progression free survival, resulted in greater toxicity than placebo and atezolizumab hence, as per Delveinsight's analysis this is not a safe and effective treatment option for relapse/refractory Triple Negative Breast Cancer patients.


Refer to Triple Negative Breast Cancer Market report for detailed Insights.